scholarly journals A novel therapeutic strategy of lipidated promiscuous peptide against Mycobacterium tuberculosis by eliciting Th1 and Th17 immunity of host

2016 ◽  
Vol 6 (1) ◽  
Author(s):  
Pradeep K Rai ◽  
Sathi Babu Chodisetti ◽  
Sajid Nadeem ◽  
Sudeep K Maurya ◽  
Uthaman Gowthaman ◽  
...  
Keyword(s):  
Mycobacterium Tuberculosis ◽  
Therapeutic Strategy ◽  
Promiscuous Peptide ◽  
Novel Therapeutic

Anti-OX40ligand treatment as a novel therapeutic strategy in a murine model of colitis

2001 ◽  
Vol 120 (5) ◽  
pp. A685-A685
Author(s):  
B SINGH ◽  
V MALMSTROM ◽  
F POWRIE
Keyword(s):  
Murine Model ◽  
Therapeutic Strategy ◽  
Novel Therapeutic

Anticancer Immunotoxins, Challenges, and Approaches

2020 ◽  
Vol 26 ◽  
Author(s):  
Maryam Dashtiahangar ◽  
Leila Rahbarnia ◽  
Safar Farajnia ◽  
Arash Salmaninejad ◽  
Arezoo Gowhari Shabgah ◽  
...  
Keyword(s):  
Therapeutic Strategy ◽  
Antibody Fragment ◽  
Clinical Use ◽  
Multiple Cancer ◽  
Main Obstacle ◽  
Cancer Types ◽  
Recombinant Immunotoxins ◽  
Cancerous Cells ◽  
High Immunogenicity ◽  
Novel Therapeutic

: The development of recombinant immunotoxins (RITs) as a novel therapeutic strategy has made a revolution in the treatment of cancer. RITs are resulting from the fusion of antibodies to toxin proteins for targeting and eliminating cancerous cells by inhibiting protein synthesis. Despite indisputable outcomes of RITs regarding inhibiting multiple cancer types, high immunogenicity has been known as the main obstacle in the clinical use of RITs. Various strategies have been proposed to overcome these limitations, including immunosuppressive therapy, humanization of the antibody fragment moiety, generation of immunotoxins originated from endogenous human cytotoxic enzymes, and modification of the toxin moiety to escape the immune system. This paper devoted to reviewing recent advances in the design of immunotoxins with lower immunogenicity.

scholarly journals Targeting ferroptosis: A novel therapeutic strategy for the treatment of mitochondrial disease-related epilepsy

PLoS ONE ◽  
2019 ◽  
Vol 14 (3) ◽  
pp. e0214250 ◽  
Author(s):  
Amanda H. Kahn-Kirby ◽  
Akiko Amagata ◽  
Celine I. Maeder ◽  
Janet J. Mei ◽  
Steve Sideris ◽  
...  
Keyword(s):  
Mitochondrial Disease ◽  
Therapeutic Strategy ◽  
Novel Therapeutic

scholarly journals Apohemoglobin-haptoglobin complex attenuates the pathobiology of circulating acellular hemoglobin and heme

2020 ◽  
Vol 318 (5) ◽  
pp. H1296-H1307 ◽  
Author(s):  
Carlos J. Munoz ◽  
Ivan S. Pires ◽  
Jin Hyen Baek ◽  
Paul W. Buehler ◽  
Andre F. Palmer ◽  
...  
Keyword(s):  
Therapeutic Strategy ◽  
Capillary Density ◽  
Microvascular Blood Flow ◽  
Systemic Hypertension ◽  
Proof Of Concept ◽  
Heme Transfer ◽  
Ligand Transfer ◽  
Novel Therapeutic

This study highlights the apoHb-Hp complex as a novel therapeutic strategy to attenuate the adverse systemic and microvascular responses to intravascular Hb and heme exposure. In vitro and in vivo Hb exchange and heme transfer experiments demonstrated proof-of-concept Hb/heme ligand transfer to apoHb-Hp. The apoHb-Hp complex reverses Hb- and heme-induced systemic hypertension and microvascular vasoconstriction, preserves microvascular blood flow, and functional capillary density. In summary, the unique properties of the apoHb-Hp complex prevent adverse systemic and microvascular responses to Hb and heme-albumin exposure and introduce a novel therapeutic approach to facilitate simultaneous removal of extracellular Hb and heme.

Subcutaneous BNP administration in experimental mild heart failure: A novel therapeutic strategy

1998 ◽  
Vol 4 (3) ◽  
pp. 19
Author(s):  
HH Chen ◽  
JA Grantham ◽  
JA Schirger ◽  
M Jougasaki ◽  
O Lisy ◽  
...  
Keyword(s):  
Heart Failure ◽  
Therapeutic Strategy ◽  
Mild Heart Failure ◽  
Novel Therapeutic

scholarly journals MiR-29a: a potential therapeutic target and promising biomarker in tumors

2018 ◽  
Vol 38 (1) ◽  
Author(s):  
Jin-yan Wang ◽  
Qian Zhang ◽  
Dan-dan Wang ◽  
Wei Yan ◽  
Huan-huan Sha ◽  
...  
Keyword(s):  
Cell Proliferation ◽  
Therapeutic Target ◽  
Therapeutic Strategy ◽  
Transcriptional Level ◽  
Additional Insight ◽  
Potential Therapeutic Target ◽  
Rna Molecules ◽  
Non Coding Rna ◽  
Non Coding Rnas ◽  
Novel Therapeutic

MiRNAs, small non-coding RNA molecules, were recognized to be associated with the incidence and development of diverse neoplasms. MiRNAs were small non-coding RNAs that could regulate post-transcriptional level by binding to 3′-UTR of target mRNAs. Amongst which, miR-29a was demonstrated that it had significant impact on oncogenicity in various neoplasms through binding to critical genes which enhanced or inhibited the progression of cancers. MiR-29a participated in kinds of physiological and pathological processes, including virus replication, cell proliferation, differentiation, apoptosis, fibrosis, angiogenesis, tumorigenicity, metastasis, drug-resistance, and so on. According to its sufficient sensitivity and specificity, many studies showed that miR-29a might serve as a potential therapeutic target and promising biomarker in various tumors. In this review, we discussed the functions of miR-29a and its potential application in the diagnosis, treatment and stages of carcinoma, which could provide additional insight to develop a novel therapeutic strategy.

Sign in / Sign up

Export Citation Format

Share Document